Podcasts about hcps

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Download the transcript here

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Listen to the podcast here

Our 82nd episode features a fantastic conversation with Dr. Sarah Felknor, leader of the University of Texas' School of Public Health's Southwest Center for Environmental and Occupational Health Sciences! Dr. Felknor is a prolific and accomplished professional in the academic, research, and occupational/industrial spaces throughout many industries and programs; we're happy she gave such great insight into their programs and opportunities. Thanks!

Patients are playing a more active role in healthcare decisions as part of a shifting ecosystem that includes HCPs, payers, employers, advocacy groups and industry. This episode explores how lived experience is shaping influence, trust and the patient value equation (outcomes, access, affordability and experience), and what pharma and biotech teams can do to partner responsibly while creating measurable value. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our 81st episode features Part 2 of our fantastic conversation with Catherine Mattice of Civility Partners on psychological safety and how it relates to healthcare, public service, occupational safety and health, and more. Thanks for hanging out with us again, Catherine!

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Fear of retaliation keeps many people trapped in high conflict relationships long after they know they need to leave. Emotional explosions, smear campaigns, threats involving children, financial punishment, legal warfare — the threat of what might happen when you finally say the words can feel more paralyzing than staying. The Betty Broderick case is an extreme example, but the dynamic it illustrates — unmanaged emotions, all-or-nothing thinking, and escalating revenge — shows up in milder forms in relationships every day.Bill Eddy, LCSW, JD, and Megan Hunter, MBA, co-founders of the High Conflict Institute, walk through what a safer, stepwise exit actually looks like — and why an abrupt in-person announcement is the most dangerous approach. They cover the biggest mistakes people make when leaving, how to document behavior and prepare for false allegations before they happen, and what courts and police actually respond to when you present your situation.It's All Your Fault is produced by TruStory FM.Full Show Notes & ResourcesSubmit Questions | Bookstore | WebsiteWatch this episode on YouTubeImportant Notice: Our discussions focus on behavioral patterns rather than diagnoses. For specific legal or therapeutic guidance, please consult qualified professionals in your area. (00:00) - Welcome to It's All Your Fault (02:26) - Betty Broderick Case (11:01) - Why People Are Afraid to Leave Relationships with HCPs (14:04) - Mistakes When Trying to Leave (17:06) - Creating Escalations (20:11) - When It's Not a Marriage (21:48) - Getting Prepared (28:04) - Giving Warning (28:47) - If on the Fence (30:17) - Wrap Up

ASCO is the preeminent cancer conference, bringing every oncology stakeholder to Chicago for a weekend of breakthrough presentations, pertinent health discussions and a bevy of brand activations. Additionally, MM+M will be on the ground there, represented by pharma editor Lecia Bushak. Ahead of ASCO, Lecia chatted with Illinois CancerCare's Kimberly Ku, MD. A triple board-certified physician, Ku recently partnered with Cancer Therapy Advisor, a fellow Haymarket Media brand, to distribute her podcast, Val-You Based Care.  Now, she's joining our podcast for a preview of ASCO as well as to offer insights on how pharma brands can better message to HCPs and patients about cancer care. After that, I'm shipping up to Boston for the Veeva Commercial Summit, so you'll hear from the rest of the team during Trends, where they'll discuss some of the most interesting trends they've observed through their reporting for Agency 100.   Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our 80th episode features a fantastic conversation with Sean Small at the City of Houston on the importance of Employee Assistance Programs, how they function, and their connections to Occupational Safety and Health. Thanks, Sean!

Nella mattinata di mercoledì 6 maggio, in Degiornalist - Gli Spaccanotizie, Fabiana e Claudio Chiari hanno ospitato il professor Matteo Bassetti per analizzare la preoccupante diffusione dell' hantavirus (Hcps) a bordo di una nave da crociera, evidenziando una dinamica epidemiologica insolita. «Questo è un virus che normalmente è trasmesso agli uomini dai roditori. Però qui si è di fronte a una situazione molto diversa rispetto a come pensavamo: c'è un primo caso che probabilmente è stato contagiato dai topi, mentre negli altri casi il contagio è avvenuto da uomo a uomo. E questo oggi mette un grandissimo punto interrogativo su tutta la vicenda», commenta il Professor Bassetti analizzando la questione, che ora richiede un massiccio sforzo di tracciamento dei contatti a livello internazionale. L'esperto critica la gestione dell'emergenza da parte delle autorità marittime, sottolineando come i lunghi tempi di incubazione e le difficoltà logistiche rendano necessario un rigoroso isolamento dei passeggeri a terra. Il professor Matteo Bassetti fa dunque chiarezza sulla gravità del caso, che smette di essere una crisi locale per diventare un giallo sanitario globale che coinvolge anche i trasporti aerei.

Our 79th episode features a great conversation with Catherine Mattice with Civility Partners on Psychological Safety in Healthcare and across all industries. Thanks to Catherine for joining us and the fantastic discussion!

Suzy Jackson, a digital health specialist focusing on Patient Tech, highlights the shift in the pharmaceutical industry from a provider-focused model to direct engagement with patients. Using AI to create a more consumer-like, personalized healthcare experience will benefit patients and inform researchers and providers about adherence to care and drug side effects.  Patient Tech helps reach underserved populations and moves from providing information to a proactive environment, enabling action and more informed discussions with healthcare providers. Suzy explains, "So everything for me in the Patient Tech space is anything that helps a patient find care, navigate care options, or indeed stay on care, including anything to do with lifestyle interventions and preventative care as well. So I think the category is expanding very, very rapidly, and I'm excited to see what will go on in the next few years." "Well, I think it's pretty safe to say that this is a new venture for the pharmaceutical industry as a whole. I think traditionally, a lot of time has been spent on ACP education and thinking about how we make HCPs aware of all the choices and therapeutic interventions that are available for their patients. But in the last couple of years, we've really seen a shift, and I think that's caused by a multitude of different factors I'm sure we can speak about, but there's really been a shift to standing on the frontline with patients for pharma and making sure that they're providing patients with care that otherwise patients are going to find in other spaces."  #PatientTech #DigitalHealth #AI #HealthcareInnovation #PatientCenteredCare #HealthEquity #PharmaTech #HealthTech #PatientExperience #WomenInHealth #HealthInnovation #AIinHealthcare #HealthcareLeadership #FutureOfHealth #Lifesciences #PharmaDTP suzy-jackson.com Download the transcript here  

Suzy Jackson, a digital health specialist focusing on Patient Tech, highlights the shift in the pharmaceutical industry from a provider-focused model to direct engagement with patients. Using AI to create a more consumer-like, personalized healthcare experience will benefit patients and inform researchers and providers about adherence to care and drug side effects.  Patient Tech helps reach underserved populations and moves from providing information to a proactive environment, enabling action and more informed discussions with healthcare providers. Suzy explains, "So everything for me in the Patient Tech space is anything that helps a patient find care, navigate care options, or indeed stay on care, including anything to do with lifestyle interventions and preventative care as well. So I think the category is expanding very, very rapidly, and I'm excited to see what will go on in the next few years." "Well, I think it's pretty safe to say that this is a new venture for the pharmaceutical industry as a whole. I think traditionally, a lot of time has been spent on ACP education and thinking about how we make HCPs aware of all the choices and therapeutic interventions that are available for their patients. But in the last couple of years, we've really seen a shift, and I think that's caused by a multitude of different factors I'm sure we can speak about, but there's really been a shift to standing on the frontline with patients for pharma and making sure that they're providing patients with care that otherwise patients are going to find in other spaces."  #PatientTech #DigitalHealth #AI #HealthcareInnovation #PatientCenteredCare #HealthEquity #PharmaTech #HealthTech #PatientExperience #WomenInHealth #HealthInnovation #AIinHealthcare #HealthcareLeadership #FutureOfHealth #Lifesciences #PharmaDTP suzy-jackson.com Listen to the podcast here  

Assembled Intelligence and InVibe surveyed 150 U.S.-based physicians across 12 specialties to understand how healthcare professionals find, evaluate and act on clinical information in an increasingly fragmented digital environment. The research reveals a four-stage digital journey, a conditional and growing role for AI tools and a meaningful generational divide in how physicians approach new technology. In this conversation, we sit down with Assembled Intelligence's Chuck Hemann and InVibe's Christopher Farina to discuss what the data means for pharma marketers and communicators trying to reach HCPs on their terms. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In our 77th episode, Dr. Jooyeon Hwang with the University of Texas tell us about her ongoing research with the Houston Fire Department on Firefighter neurotoxin and carcinogen exposure prevention. Thanks!

Our 78th episode features a great conversation with Dr. Tran, Director of Public Health for the City of Houston (Houston Health Department), on the importance of Public Health and how Occupational Safety is a crucial part of enabling Public Health operations. Thanks, Dr. Tran!

Over the past week, everyone has had launches on the brain – thanks largely to the Artemis II rocket and its ongoing lunar flyby mission. However, there are a couple of health-related launches that are the focus of this week's episode. First up is the launch of HayloARC, a health-focused demand-side platform – better known as a DSP. HayloARC is available for use by advertisers and medical marketing agencies seeking to better interface with HCPs and patients. To accomplish this, HayloARC utilizes first-party HCP data derived from 30-plus medical publications owned by Haymarket Media, the parent company of MM+M. For the feature conversation, editor-at-large Steve Madden sits down with Louis Naimoli, VP of programmatic business development and strategy at Haymarket, about what HayloARC is, how it's differentiated from other DSPs and what it offers programmatic buyers in medical marketing. Then, during our Trends segment, we're talking about how the fight for GLP-1 supremacy between Novo Nordisk and Eli Lilly has shifted to the oral obesity pill battlefield. We discuss Novo rolling out a multimonth subscription program for Wegovy and the FDA's approval of Lilly's daily oral weight loss drug Foundayo. Music: “Deep Reflection” by DP and Triple Scoop Music. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

VPM News Host Lyndon German and BizSense Reporter Jonathan Spiers discuss the Richmond's region's top business stories starting with the forced auction of the old Model Tobacco building, Richmond's proposed spending plan and a students from Henrico County sharpening their entrepreneurial skills in Shark-tank-style competition.

A partnership between Henrico County and Dominion Energy is providing free solar panels to some Henrico homeowners; a county man faces a charge in connection with his father's death; applications being accepted for HCPS' free Early Learning Preschool program; your chance to help shape the future of Brook Road and the Best Products Reimagined site in Northern Henrico; our Weekend Top 5.Support the show

Our 76th episode features a detailed conversation with BK Masada of Masada Tactical on one of our most frequently requested topics, Workplace Violence and Active Shooter Prevention and Response. BK has a prolific career in military operations (including his 20+ year career in the Israeli Defense Force, of which he is still in), law enforcement, security, and consulting/education; we're happy he joined us to share his wealth of knowledge and experience. Thanks!

Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights the practical shifts required to get there — from cross‑functional adoption and workflow‑embedded insights to attribution modeling, efficiency gains, and focused pilots that prove value quickly. This episode is sponsored by ODAIA. Learn how brands work with Emerj and other Emerj Media options at emerj.com/partner. Want to share your AI adoption story with executive peers? Click emerj.com/expert for more information and to be a potential future guest on the 'AI in Business' podcast!

Our 75th episode features returning guest Victor Lawe and a thorough discussion of military methods such as the Operations Order and how they relate to occupational safety and ICS operations. Thanks, Victor!

Since podcasting came into existence in the mid-2000s, the space has become increasingly popular, remarkably lucrative and unquestionably saturated. Still, despite the countless millions of podcasts out there, countless millions of people tune in every hour of every day for conversations about every topic – including healthcare.  Joining a world occupied by This Past Weekend, Good Hang and The MM+M Podcast is The Persistence Lab. Launched by AbbVie's corporate affairs team, The Persistence Lab is the pharma giant's 10-episode project to highlight the work undertaken by its researchers, the clinical expertise of HCPs as well as the lived experiences of patients.  The first episode of The Persistence Lab was released late last week and is available wherever you listen to your podcasts.Molly James-Lundak, VP of R&D communications at AbbVie, joined me for a slightly meta conversation about joining the podcast sphere, how the drugmaker brought the idea to life and why it was important to engage with audio content creation.   And for our Trends segment, we're talking about AI in healthcare: Including the tools that actually work, the regulations on the way and the concerns that never go away.  Music: “Deep Reflection” by DP and Triple Scoop Music.   Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

The term "omnichannel engagement" has become embedded in today's healthcare conversations. Yet the biopharmaceutical industry often approaches it superficially – treating it as a trendy buzzword instead of a meaningful strategy for connecting with the sector's two most vital audiences: patients and healthcare providers (HCPs). In this episode of the pharmaphorum podcast, developed in partnership with Reverba Global, editor-in-chief Jonah Comstock sits down with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of clinical and medical client services, to discuss how a thoughtfully executed omnichannel strategy can empower scientific experts to become effective communicators. Today's patients actively seek scientifically robust, yet accessible, information about their health conditions, and a well-integrated medical affairs strategy can help deliver that knowledge through the HCPs they trust most. However, bringing this vision to life requires forward-thinking strategies that build authentic connections, challenge conventional approaches, and dismantle the communication silos that frequently exist in healthcare organisations. Throughout the episode, Lubbert and Whiting share Reverba Global's methodology for authentic omnichannel engagement with patients and physicians, offering real-world examples and practical perspectives on navigating obstacles and establishing this evolved model. You can listen to this episode of the pharmaphorum podcast using the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Children can experience illnesses and will often encounter procedures which can cause pain when they attend or are admitted to hospital. This experienced pain may be acute, chronic and/or persistent in nature. National and International guidelines are available directing Healthcare practitioners (HCPs) on how to assess and manage pain. Despite this, the assessment and management of children's pain remains a challenge within healthcare teams, and the burden of pain in children, and its impact on families and society is significant (Eccleston et al., 2021). So, let's shine a light on pain across our healthcare curriculums and in our healthcare settings to ensure that our patients get the best possible, evidence-based care and avoid the fear and lack of confidence that their pain will be managed appropriately. We have a responsibility to review our education provision to ensure that specified content is included, we need to call for improved CPD funding for staff and we need to increase awareness within the healthcare setting of the short- and long-term impact of untreated pain in children.

Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT Recorded on January 8, 2026 Chelsey Winegar, LCSW, MBA Manager of Oncology Services Intermountain Health Murray, UT Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve. Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today! Mentioned on this episode: Trauma Stewardship Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

CME credits: 1.00 Valid until: 16-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-care-for-the-brain-prevention-and-early-detection-of-cognitive-decline/39897/ In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.=

In this episode of the IRH Clinician's Corner, IRH lead practitioner Sara Fields sits down with Star Edwards, Healthcare Practice Director at Tiny Health, for an enlightening conversation about the evolution of gut health diagnostics—especially in pediatrics, but with insights spanning all ages. From understanding key differences between pediatric and adult microbiomes to exploring innovative metrics like HMO digestion and inflammatory markers, Sara Fields and Star Edwards make this complex data approachable, actionable, and relevant.   In this interview, we discuss:   The origins of Tiny Health and what sets them apart from other microbiome testing The importance of first 1,000 days for immune and neurodevelopment Tiny Health's suite of tests Comparing whole genome sequencing to other methods of testing (like PCR) Key results categories/metrics and examples of markers unique to Tiny Health Clinical applications and insights The Clinician's Corner is brought to you by the Institute of Restorative Health. Follow us: https://www.instagram.com/instituteofrestorativehealth/   Connect with Star Edwards/Tiny Health: Website: https://www.poweredbytiny.com/ LinkedIn: https://www.linkedin.com/in/star-edwards/   For practitioners looking to open an account with Tiny Health and order test kits, go to https://www.poweredbytiny.com/practitioners   Use discount code IRH2025 to receive $50 off your first Gut Health or PRO Gut Health test  For more resources, including sample reports, research, report walkthroughs, and interpretation guides: https://www.poweredbytiny.com/resources   Timestamps:  00:00 Passion for Microbiome and Nutrition 09:06 "Microbiome's Role in Early Development" 11:36 HMO Digestion and Infant Health 20:23 "Functions: The Frontier of Microbiome" 21:32 Microbiome Functions and Health Connections 30:00 Microbiome Patterns and Health Insights 34:36 Microbiome Differences Across Ages 42:08 "LPS: Gut Inflammation Explained" 47:59 "Tiny Health's Key Insights" 50:03 Microbiome Balance Through Testing 58:40 "H. Pylori Testing Advice" 01:02:02 Personalized Microbiome Testing Benefits Speaker bio:  Star is a former WIC high-risk dietitian and has helped her own clients in private practice, focused on food allergies and sensitivities, gastrointestinal conditions, athletic performance, and pediatrics. For much of her career, she has worked for food allergy and microbiome testing companies, training and mentoring health care practitioners on test interpretation and microbiome recovery protocols. As the Healthcare Practice Director of Tiny Health, she works closely with HCPs to assure Tiny Health testing is actionable and helps them solve their patient microbiome grievances.   Keywords:  functional health, microbiome testing, Tiny Health, gut microbiome, pediatrics, food allergies, eczema, atopic march, C-section birth, whole genome sequencing, stool chemistry, probiotics, dietary recommendations, immune system, chronic disease, practitioner resources, reference ranges, short chain fatty acids, HMO digesting species, LPS (lipopolysaccharide), TMA (trimethylamine), neurodevelopment, inflammation, GI health, diversity in microbiome, beneficial microbes, disruptives/pathogens, action plan, clinical insights, gut-brain connection Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center […]

As Gen Z steps into the healthcare workforce, they're bringing new expectations for authenticity, technology, and purpose-driven brands. The old pharma playbook? Invisible to this generation.In this episode of Trending Health, host Adrea Cope sits down with Carolyn Frantz and Mindy McGrath to explore how life sciences marketers can evolve to engage the next generation of HCPs and patients — from short-form content and streaming-first strategies to redefining the pharma rep of the future.To learn more about how we can help your team navigate these changing landscapes, please reach out to Carolyn.Frantz@vynamic.com or Mike.Zapiec@vynamic.comPodcast Tags: healthcare, life sciences, life sciences marketing, Gen Z, digital health, brand authenticitySource Links:Gen Z more likely to report mental health concernsGeneration X Faces Higher Cancer Rates Than Boomers: StudyPanel – Adrea Cope, Carolyn Frantz, Mindy McGrathResearch & Production – Adrea Cope, Carolyn Frantz, Hannah Yee, Mike ZapiecRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com.

A new limited series of the Syneos Health Podcast, Conversations on Commercialization unpacks how biopharma leaders are rewriting the commercial playbook, redefining what it takes to succeed.  Recorded at Fierce Pharma Week 2025, the series begins with a two-part conversation with Mark Bard, co-founder of the Digital Health Coalition. In this episode, Bard joins host Tyler Cowan, VP, Commercial at Syneos Health to unpack how the pandemic reshaped provider expectations and the continued impact on commercial teams. From feedback loops to content fatigue, to the myth of multichannel mastery, they break down what it takes to engage HCPs on their terms. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Medical marketing is faced with gale-force winds of uncertainty, so we're going to spend most of this week's episode focused on the industry's future but in two distinct ways.For our feature interview, we're joined by recurring guest Andrea Palmer, the CEO of Publicis Health Media, as well as Brad Liebow, who recently jumped from Spark Foundry to become PHM's first chief investment officer.The pair explain why the position was established, how it is designed to further differentiate PHM from other medical marketing agencies and how they assess the modern health media landscape.After that is our Trends segment, where we'll discuss the Trump administration's press conference tying the usage of Tylenol among pregnant women to the rise in cases of autism.The announcement, while widely-expected, was presented to the American people without solid evidence – so we'll dive into what it all means for health brands like Tylenol manufacturer Kenvue as well as medical marketers and HCPs.We'll also do a bit of housecleaning on those Untitled Letters from the FDA as part of the ongoing DTC pharma ad crackdown. Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.  Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES: 1. SMILE Study: A randomized, placebo-controlled trial of hydroxychloroquine in incomplete lupus  https://t.co/NnrA8ohiGX 2. Equal Safety of JAK Inhibitors and TNF Inhibitors in H2H IMID trials JAMA systematic review.  https://t.co/HI1KBKZiXR 3. SMART study - Single vs. Split Dose Methotrexate  https://t.co/lizsrtVHwf 4. Vegan diets don't work in RA - Metanalysis of 7 studies https://t.co/jeh6gN5Byg 5. No association between IL-17 inhibitors & MACEs (vs TNFi Rx)  https://t.co/fJuPFYKnSr https://t.co/Vscnsq0DTA 6. Successful Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) https://t.co/8p1FvJx0s0 7. Anifrolumab effective & safe in refractory Cutaneous LE - OL Study in 15 CLE https://t.co/umEYz0XDyt 8. "Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead https://t.co/OFGN223bPa

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration.   In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0.   Having spent more than two decades working at the intersection of healthcare professionals, patients, and technology, Silber has had a front row seat to the evolution of digital tools in the sector. From the early adoption of electronic health records to the integration of new artificial intelligence, she has witnessed dramatic shifts across life sciences, yet at the heart of her work remains the core focus of patient centricity.   In this interview, she discusses the importance of spotlighting patient centricity at Frontiers Health, what makes the event special, and her favourite moments from years gone by.  

Explore the latest trends in HCP content consumption and how pharma marketers can adapt their strategies to reach their target audience effectively with The Trade Desk's senior director of business development Lindsay Reardon and Swoop's VP of client success Kevin Elwell. They will share research insights into how HCPs engage online, highlighting the growing importance of CTV and audio channels, how a data-driven approach can break down silos between HCP and DTC campaigns and how to elevate patient and HCP engagement strategies. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. Features Dr. Jack Cush, Editor at RheumNow.com.

In Breaking the Code's 50th episode, we are joined by our 2025 summer intern, Gabriel Robinson (GR), not to be confused with Gabriel Allen-Cummings (GA). This conversation began because of GR's curiosity about social media being used for self-diagnosis, and it evolved to cover HCPs on social media, generational nuances in social media use, and the emergence of AI as a comprehensive caregiver.Follow us on LinkedIn

Send us a textDr. Duplantis and Dr. Horowitz are holding down the fort this week by bringing you answers to all the burning questions you have about what goes into hiring an associate at your dental practice. From pre-hire preparation to planning a seamless onboarding process, the DINKs have you covered!

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Continuing our vital conversation from GLP-1s & Men's Health: Jhon Henri's Weight Loss Story P1, we welcome Dr. Catherine Toomer an expert on weight management, who offers her insights on weight, health, and metabolic well-being. Building on Jhon Henri's powerful story and how GLP1s changed his life, Dr. Toomer unpacks the complexities of obesity as a disease, the limitations of BMI, and why the focus should shift from simple weight loss to metabolic correction.Discover why societal views on weight, particularly for men, contribute to healthcare disparities, and how GLP-1 medications work beyond "food noise" to address underlying metabolic issues. Dr. Toomer also sheds light on the often-misunderstood connection between rapid weight loss and gallstones, and candidly discusses the physiological changes women experience during perimenopause and menopause, including the role of estrogen decline in weight gain.This episode is a must-listen for anyone seeking a deeper understanding of chronic weight management, the importance of advocating for your health, and the journey toward holistic well-being.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez____________________________Send us Fan Mail!Diabetes dialogues podcastDiabetes insights for HCPs. Dexcom's expert-led podcast, Diabetes Dialogues.Listen on: Apple Podcasts SpotifySupport the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Empowerment and Success Against the Odds: Kelsey Lewis' Journey with DiabetesIn this episode of The Pediatric Lounge podcast, hosts George and his co-host welcome Kelsey Lewis, a registered dietitian and certified diabetes care specialist. Diagnosed with type 1 diabetes at 17, Kelsey turned her personal challenges into a professional mission. She shares her journey from being told she couldn't be a collegiate athlete to proving her doubters wrong. After her clinic was shut down due to financial priorities, Kelsey established a thriving private practice that now serves 23 states through telemedicine. Her resilient story underlines the importance of not letting others define your limits, the transformative power of education, and the need for independent practices to prioritize patient outcomes over profitability.00:00 Introduction to The Pediatric Lounge00:37 Meet Kelsey Lewis: A Journey from Athlete to Diabetes Specialist01:28 Kelsey's Diagnosis and Early Challenges02:52 Overcoming Obstacles: From High School to College Athlete11:17 Transition to Professional Life and Systemic Challenges23:50 Establishing a Private Practice and Expanding Nationwide27:47 Telemedicine Success and Future Prospects28:53 Lessons in Resilience and Overcoming Adversity30:45 Partnering with Medical Practices for Better Outcomes35:26 Challenges and Advocacy in Pediatrics40:30 The Impact of Sugar and Salt on Health49:32 Final Thoughts and Advice for ParentsYou can connect with Kelsie here. Diabetes dialogues podcastDiabetes insights for HCPs. Dexcom's expert-led podcast, Diabetes Dialogues.Listen on: Apple Podcasts SpotifySupport the show

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We break down the key differences between Tylenol (acetaminophen) and NSAIDs (ibuprofen, naproxen, aspirin) to help you make informed decisions about which pain reliever is right for you. This evidence-based discussion draws from top medical sources to explain how these common medications work differently in your body.• Tylenol works on perception of pain and fever in the brain but doesn't address inflammation• NSAIDs reduce pain, fever AND inflammation by blocking the prostaglandin cascade• Both medications are commonly used for everyday pain including headaches and general discomfort• NSAIDs are usually more effective for inflammatory conditions like sprains, arthritis, and period cramps• Tylenol's main risk is liver damage at high doses (max 4,000mg daily for most adults)• NSAIDs can cause stomach ulcers, GI bleeding, increased blood pressure, and kidney problems• Consider your medical history when choosing—liver issues (caution with Tylenol), stomach/heart/kidney problems (caution with NSAIDs)• Age is a factor—older adults generally face higher risks with NSAIDs• Taking NSAIDs with food can help reduce stomach problems• Always read labels and follow dosing instructions carefullyShare this episode with friends or family who take these medications regularly to help them understand what they're putting in their bodies.Diabetes dialogues podcastDiabetes insights for HCPs. Dexcom's expert-led podcast, Diabetes Dialogues.Listen on: Apple Podcasts SpotifySupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Send me a message - text me! Last night, a trip to a familiar venue for my weekly pool match brought back a memory I hadn't felt in years. I was ten years old, dancing in front of a mirror in the toilets, completely lost in joy. I wasn't worrying about my body. I wasn't thinking about food. I was just happy.In this episode, I share what it felt like to reconnect with that version of me, and how soon after diet culture crept in and began to change everything. This is a personal and emotional reflection on body image, childhood innocence, and the moment things started to shift.I talk about what I'd say to my younger self now, how we can all learn from those early memories, and what it means to heal the relationship with your body and reclaim the joy that was once yours.Whether you've lost touch with your younger self or you're working on healing your body image, this episode is a gentle reminder that she's still in there. She always was. Maybe she just needs a little coaxing back out.

Rural Pediatrics: A Conversation with Dr. Eric TylerIn this episode of The Pediatric Lounge, hosts George and Herb welcome Dr. Eric Tyler, a seasoned pediatrician with over 40 years of experience in rural Alabama. Dr. Tyler shares his journey into pediatrics, inspired by his childhood experiences and his work ethic instilled by his farming upbringing. He discusses the unique challenges and rewards of practicing pediatrics in a rural setting, addressing the impact of adverse childhood experiences and the importance of community engagement. Dr. Tyler emphasizes the need for systemic changes in healthcare funding and education to better support rural pediatricians and their patients. He also shares innovative community initiatives aimed at improving children's health and well-being, including a meditation program for local schools and telehealth services for mental health. The conversation underscores the importance of rethinking dogma in medical practice to better meet the needs of underserved populations.00:00 Introduction to The Pediatric Lounge00:28 Meet Dr. Eric Tyler: A Rural Pediatrician01:22 Dr. Tyler's Journey into Medicine01:34 Life on the Farm and Early Influences03:03 Medical Training and Early Career04:34 Challenges and Rewards of Rural Pediatrics15:09 Community Engagement and Initiatives24:24 HPV Vaccination Success24:41 Challenges of Accessing Specialists25:16 Project Echo and Telehealth Services27:22 Medicaid and Healthcare System Issues36:38 Adverse Childhood Experiences41:22 The Importance of Community and Family50:00 Loneliness and Mental Health53:09 Reflections on Rural MedicineDiabetes dialogues podcastDiabetes insights for HCPs. Dexcom's expert-led podcast, Diabetes Dialogues.Listen on: Apple Podcasts SpotifySupport the show

Send us a message with this link, we would love to hear from you. Standard message rates may apply.PCOS affects approximately one in ten women of reproductive age, creating a cascade of symptoms from irregular periods to fertility challenges. This common hormonal and metabolic condition has implications for long-term health beyond just reproductive concerns, including increased risk for diabetes, heart disease, and mental health issues.• PCOS is characterized by elevated androgens and insulin resistance• Symptoms include irregular periods, acne, unwanted hair growth, and weight management challenges• Diagnosis requires meeting at least two of three Rotterdam criteria: irregular periods, high androgens, and polycystic ovaries• Having ovarian cysts alone does not mean someone has PCOS• PCOS increases risk for type 2 diabetes, high blood pressure, sleep apnea, and even endometrial cancer• First-line treatment involves lifestyle modifications including diet and regular exercise• Even modest weight loss (5-10%) can significantly improve symptoms• Mental health support is crucial as PCOS is associated with higher rates of anxiety and depression• Medication options include birth control pills, metformin, fertility medications, and anti-androgen treatments• Free resources like the Ask PCOS app and online support groups can provide additional helpShare this episode with someone who might benefit from understanding PCOS better. Send us your thoughts at yourcheckuppod@gmail.com.Diabetes dialogues podcastDiabetes insights for HCPs. Dexcom's expert-led podcast, Diabetes Dialogues.Listen on: Apple Podcasts SpotifySupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Send us a textIs everything you've heard about carbs, seed oils, and diabetes wrong? Dr. Westman and Bart Kay dig into the real science.

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the programHear Me: Patient Perspectives on PBC

In late 2024 I spoke with an academically trained cardiologist expert in cardiometabolic risk prevention and obesity medicine, educator, Dr. Eldad Einav, from Beverly Hills, CA about the ongoing controversy about the shortage and patient access to the exciting new weight loss treatments such as GLP1 agonists. He shared many practical, clinical insights and research that are important to revisit today for patients, physicians, and payers who are seeking to provide the best solutions and learn from some recent shortcomings.0:00 Highlight #1 - Distinguishing the quality of weight loss solutions1:26 Highlight #2 - Providing reliable 503B Facility source for patients w/ no access to GLP13:18 - Speaker Introduction6:14 - Why Dr. Einav decided to specialize in obesity / weight loss9:38 - Why should cardiologists focus on weight management - preventive care?11:58 - Not many cardiologists manage weight12:34 - Patient preferences to treat weight vs hypertension or cholesterol14:34 - Problem of maintaining long-term weight loss 15:00 Look AHEAD study - well-controlled lifestyle study of weight loss with 16:19 Drugs meeting newer targets of 15% or higher weight loss16:57 - Select Trial: weight loss reduces risk of heart attack, stroke by 20%19:07 - New drugs approaching efficacy of bariatric surgery 21:29 - 2024 Shortage and patient access to new GLP1 drugs23:11 - Specialty pharmacy compounding GLP controversy26:06 - What doctors should know about choosing compounded drug alternatives27:54 - What patients should know about choosing their weight loss drugs31:22 - Reality of types of compounded medications used by US hospitals32:11 - Removing the double-standard of compounded medications to improve patient access33:46 - Helpful resources to learn how to access the right weight-loss medication37:47 - Final Advice to Patients and HCPs to make better decisions, consolidate fragmented care

Healthcare providers (HCPs) are busier and more overwhelmed than ever before, meaning the customer experience can no longer be an afterthought—it must be a strategic priority. In this Trending Health episode, Everly is joined by Raina Dhir & Colleen Lawlor to tackle a challenge every launch team faces—how to break through the noise and truly connect with HCPs at launch. Raina, Colleen, and Everly explore strategies for creating personalized, high-impact HCP experiences to truly enable leaders to differentiate their launches.To learn more about how we can help your team, reach out to colleen.lawlor@vynamic.com and raina.dhir@vynamic.com. Check out our recent Omnichannel Insight on our website for more information: From strategy to execution: Delivering an omnichannel transformation – Vynamic LLC Podcast Tags: healthcare, life sciences, product launch, product launch trends, life sciences trends, launch excellence, customer engagement, customer experience Panel –Everly Petruzzelli, Colleen Lawlor, Raina Dhir Research & Production – Julia Morrison, Adrea Cope, Everly Petruzzelli  Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the fallout from major